FDA Speeds Up Eye Drug for Rare Kids' Disease with Magic Voucher
Published Date: 3/13/2026
Notice
Summary
The FDA just approved EYLEA HD (aflibercept) using a special Rare Pediatric Disease Priority Review Voucher, speeding up its review because it treats a rare childhood illness. This means the company behind EYLEA HD got a fast-track pass, helping kids get medicine sooner. Keep an eye out for more rare disease treatments moving faster thanks to this program!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Faster Approval for Rare Pediatric Drug
If you have a child with the rare pediatric condition treated by EYLEA HD, the FDA approved EYLEA HD (aflibercept) using a Rare Pediatric Disease Priority Review Voucher. The supplemental application was approved on November 19, 2025, and the voucher sped up the review so children can access the medicine sooner.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2026-04887, Flixbus SE, Flix North America Inc., and Greyhound Lines, Inc.-Control-Pacific Northwest Bus LLC
Flixbus SE, Flix North America, and Greyhound are teaming up to keep control of a new bus company called Pacific Northwest Bus LLC. The government is giving a thumbs-up to this plan, as long as no one objects by April 27, 2026. This move helps these companies keep their bus services running smoothly in the Pacific Northwest without any hiccups.
Next: 2026-04891, Agency Information Collection Activities; Submission for OMB Review; Comment Request; Fidelity Bonding Issuance
The Department of Labor is asking for public feedback on its plan to collect info about fidelity bonds that protect employers hiring people who might have a tough time getting jobs. This includes folks like recovering addicts, youth without work history, and others. Comments are open until April 13, 2026, and the goal is to make sure the info collection is useful and not too much work for anyone involved.